➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
McKinsey
AstraZeneca
Johnson and Johnson
Medtronic

Last Updated: October 22, 2021

DrugPatentWatch Database Preview

Patent: 9,089,570

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,089,570
Title:Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
Abstract: This invention provides methods and compositions useful for treating early and late stage metastatic cancer to prevent or treat acquired resistance due to gene amplification or mutation in response to chemotherapeutic and/or targeted drugs. In particular, the methods and compositions include carboxiamidotriazole orotate (CTO) alone or in combination with specific regimens of chemotherapeutic and/or targeted drugs designed to overcome the genomic resistance raised to prior therapy.
Inventor(s): Karmali; Rashida A (Brooklyn, NY)
Assignee: TACTICAL THERAPEUTICS INC (New York, NY)
Application Number:13/986,103
Patent Claims:see list of patent claims

Details for Patent 9,089,570

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2039-02-26
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Free Forever Trial 2039-02-26
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Free Forever Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Medtronic
Baxter
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.